US$ 21.83
is it illegal to compound tirzepatide Eli Lilly sues companies selling alternative versions of its weight loss drug March 10, 2025: Patients transitioning
Description
BUT what are the future growth drivers and possibly the next billion-dollar markets?

Summer temperatures across Dubai, Abu Dhabi, and other Emirates frequently exceed 45C, making proper storage essential

Glucagon-like peptide receptor agonists (GLP-1 RAs) now available to promote weight lossWegovy (semaglutide), Zepbound (tirzepatide), and Saxenda (liraglutide)could potentially make much needed gains against the obesity epidemic

Market analysts project significant expansion in this sector, with Novo Nordisk maintaining a leading position but facing increasing competition from Eli Lilly and other emerging players
